Your session is about to expire
← Back to Search
Siltuximab for Multiple Myeloma
Study Summary
This trial will investigate if blocking the protein IL-6 with the agent siltuximab will decrease symptoms after an autologous stem cell transplant, to improve quality of life and recovery.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 342 Patients • NCT04330638Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your recent medical test results need to meet certain standards set by the study.I am a man who will use protection during sex with a woman who can have children.I can care for myself and perform daily activities.I have multiple myeloma or AL amyloidosis and am getting a stem cell transplant with melphalan.You need to have at least 3 million CD34+ cells per kilogram of body weight for the infusion.I do not have HIV, hepatitis C, or active hepatitis B.I have been treated with drugs targeting IL-6 or its receptor before.I have not received any live vaccines in the last 4 weeks.Your lung function test shows that your diffusion capacity is higher than 45% of what is expected for someone with your level of hemoglobin.I am between 60 and 75 years old.I have had cancer in the past 2 years, but it's treated and not active.I am a woman aged between 60 and 75.I haven't been hospitalized for an infection or had major surgery in the last 2 weeks.
- Group 1: Siltuximab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment still possible for this medical experiment?
"This trial is not admitting patients at present. The listing on clinicaltrials.gov was initially posted in December of 2017, and recently updated in January 2022. For those searching for alternative studies, there are 895 trials recruiting multiple myeloma candidates and 4 studies utilizing Siltuximab that are actively accepting participants."
Is this investigation open to participants aged under 70 years old?
"As per the requirements of this trial, participants must be at least 60 years old and no older than 75."
To what degree do the risks of Siltuximab outweigh its potential benefits?
"As this is a Phase 2 trial, with existing data on safety but no evidence of efficacy, the team at Power assigned Siltuximab with a score of 2."
Am I a suitable candidate for participating in this medical experiment?
"This clinical trial seeks 30 elderly individuals (aged between 60-75) with multiple myeloma to participate. Specific eligibility criteria includes: CD34+ cell count of at least 3 million x 10e6/kg, diffusion capacity over 45%, KPS performance score or ECOG Performance Status score of 0-2, LVEF>45% by MUGA or rest ECHO, platelet count greater than 20x10^9/L, ALT and AST ≤ 2.5 ULN and total bilirubin ≤ 2.5 ULN; unless the rise is due to Gilbert's syndrome."
Could you please share any past research regarding Siltuximab?
"Currently, there are 4 separate studies related to the therapeutic agent siltuximab. None of these research projects have progressed into Phase 3 yet and most locations hosting trials for this medication can be found in Atlanta, Georgia. However, 6 medical sites across the country are conducting investigations with siltuximab."
To what extent is this experiment being populated by participants?
"Participation in this trial has ended, with the original posting on December 14th 2017 and final update occurring January 21st 2022. However, there are still 895 studies concerning multiple myeloma recruiting patients as well as 4 trials for Siltuximab actively enrolling participants."
Share this study with friends
Copy Link
Messenger